Quantcast
Last updated on April 18, 2014 at 16:08 EDT

Latest Echo satellite Stories

2012-08-09 02:29:35

PHILADELPHIA, Aug. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Platinum-Montaur Life Sciences, LLC (Montaur) will provide Echo a credit facility of up to $20 million. The company believes that this transaction will provide Echo with the capital...

2012-07-25 06:27:11

NEW YORK, July 25, 2012 /PRNewswire/ -- The Echo System, the return on social company, today announced the release of its second Echo Rank index, a proprietary list that gauges how ecommerce firms are leveraging social to drive sales. For the June ranking, The Echo System incorporated the latest list of top ecommerce brands and altered its ranking algorithm to place increased emphasis on how brands are integrating social into their commercial efforts. The top five companies on the June Echo...

2012-07-11 02:25:58

PHILADELPHIA, July 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that it signed an amended license agreement with Ferndale Pharma Group, Inc. ("Ferndale") that grants Ferndale the right to develop, market and sell Prelude for painless,...

2012-06-20 02:26:40

PHILADELPHIA, June 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the receipt of a notice of allowance for a patent application covering its Prelude SkinPrep System and a notice of issuance for a patent covering its Symphony tCGM System. Echo...

2012-05-30 02:25:29

PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo Therapeutics' management team at a critical stage in company growth. Mr. Walton...

2012-05-29 02:26:52

PHILADELPHIA, May 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics will present at the Jefferies 2012 Global Healthcare Conference. Dr. Mooney will make a corporate presentation to...

2012-05-08 02:25:24

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that CEO, Patrick T. Mooney, M.D. will appear on the Wednesday, May 9th airing of the popular Emmy Award-winning television show The Doctors. Dr. Mooney discusses the benefits of...

2012-04-05 02:24:07

PHILADELPHIA, April 5, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the issuance of patents covering its Prelude SkinPrep System and a notice of allowance for a U.S. patent covering its Symphony tCGM System. Patents entitled "Skin Permeation Device for...

2012-01-04 07:06:00

PHILADELPHIA, Jan. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received warrant exercises generating a total of approximately $3.6 million in cash proceeds. These warrant exercises bring the company's year-end cash balance to approximately $9.2 million. "This cash infusion, following the recent positive clinical results for use of our Symphony System, represents important achievements for Echo as we progress toward regulatory clearance...

2011-11-15 06:30:00

PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received a commitment by its largest shareholder, Platinum Partners, for a warrant exercise of $2 million. This warrant exercise will be in addition to the previously announced $1.7 million warrant exercise by Platinum. "We are very pleased with this warrant exercise as it will allow us to continue the accelerated pace of product development finalization and clinical validation...